Page 12 - Pharma Industry

Alcobev industry seek clarity on brand extension vs surrogate ads

List of products sold under the same brand name as alcobev for the past three years, including details of states where they were marketed

IVI commences tech transfer of oral cholera vaccine to Biological E

The tech transfer will be completed by 2025 and the vaccine will be manufactured for India and international markets by Biological E

Unclear how many baby formula maker cases related to Enfamil: Reckitt

Shares of Reckitt, which owns brands such as Lysol, Dettol and Strepsils, that day suffered their steepest one-day drop since 1999, making it the top loser on London's blue-chip FTSE 100

Sun Pharma's growth pill: Specialising in specialty and scaling in India

Brokerages administer confidence boost, elevating EPS forecasts and target prices for 2024-25

Govt launches programme for cashless treatment of up to Rs 1.5 lakh

The government is launching a pilot programme to provide cashless treatment to road accident victims, under which they will be entitled to cashless treatment up to a maximum of Rs 1.5 lakh per accident, an official statement said on Thursday. The statement further said the pilot programme -- being initiated in Chandigarh and developed under the aegis of the Ministry of Road Transport and Highways (MoRTH) -- is aimed at establishing an ecosystem for providing timely medical care to the victims of road accidents, including during the golden hour. "The broad contours of the pilot programme are -- victims entitled to cashless treatment up to a maximum of Rs 1.5 lakh per accident per person for a maximum period of 7 days from date of the accident," it added. The statement said claims raised by hospitals for providing treatment will be reimbursed from the Motor Vehicle Accident Fund. According to the statement, the pilot project will be applicable to all road accidents caused by the use

Aurobindo Pharma to start production of Pen-G at its Andhra plant in Q1FY25

Aurobindo Pharma expects its Rs 2,400 crore Pen-G (penicillin) plant in Andhra Pradesh to start trial production in April and commercial production in a couple of months and ramping up of production will happen during the second quarter of next fiscal, a senior official of the city-based drug maker has said. Santhanam Subramanian, Chief Financial Officer of Aurobindo Pharma, also said the company is constructing a total of 10 new facilities which are expected to capitalise in the next one to two years. Currently, the firm has a total of 25 manufacturing and packaging facilities at various locations. The plant, which was approved under Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country, will have a production capacity of around 15,000 tonnes annually. "We are doing the Pen-G project. We are in the process of installation and ...

Govt's new code bars unethical marketing of drugs by pharma firms

Medical representatives barred from using 'inducement' or 'subterfuge' to access healthcare professionals

Panel formed to administer pricing reforms for drugs, medical devices

Centre constitutes Committee for reforms in pricing framework for drugs and medical devices

Govt notifies new marketing code for pharma cos to curb unethical practices

The Department of Pharmaceuticals on Tuesday notified a new code which prohibits pharma companies from offering gifts and travel facilities to healthcare professionals or their family members. The Uniform Code for Pharmaceuticals Marketing Practices (UCPMP) 2024 also bans supply of free samples to those who are not qualified to prescribe such a product. "No gift should be offered or provided for personal benefit of any healthcare professional or family member (both immediate and extended) by any pharmaceutical company or its agent i.e. distributors, wholesalers, retailers, etc," as per the UCPMP guidelines. Similarly, no pecuniary advantage or benefit in kind may be offered, supplied, or promised to any person qualified to prescribe or supply drugs, by any pharmaceutical company or its agent i.e. distributors, wholesalers, retailers, etc, it added. Besides, the companies or their representatives, or any person acting on their behalf, should not extend travel facilities inside or ..

AstraZeneca, Mankind Pharma sign pact to distribute asthma medicine

AstraZeneca Pharma India Ltd and Mankind Pharma Ltd on Monday said they have entered into an agreement for exclusive distribution of the Symbicort brand, an asthma medicine, in India. Symbicort is owned by AstraZeneca, which will retain the intellectual property rights and will continue to be the marketing authorisation holder (MAH) and import license after the agreement, a joint statement shared on BSE by AstraZeneca Pharma India said. "The partnership with Mankind Pharma presents an opportunity to accelerate access and maximise the potential of our asthma drug as well as the turbuhaler which is a simple device, efficient in consistently delivering a higher proportion of respirable particles than the other devices," AstraZeneca India Managing Director and Country President Sanjeev Panchal said. Mankind Pharma has a distribution network, including close to 16,000 field forces and more than 13,000 stockists, across India providing access to quality pharmaceuticals across the country,

Hindustan Syringes launches Dispojekt to reduce needle stick injuries

Company aims to capture 60-70% of disposable syringes market in India

US FDA approves Eyenovia's eye drops to reduce pain: Formosa Pharma

Eyenovia acquired US commercial rights of the drug last August from Formosa

Max, Fortis, Apollo: Why are hospital stocks bleeding in a firm market?

Nifty Healthcare has outperformed Nifty50 and some individual healthcare stocks have doubled investor wealth in FY24

Advent PE begins merger process of Suven Pharma and Cohance Lifesciences

The merged platform will have mid-30s EBITDA margins, 30 per cent Return on Capital Employed (RoCE) and stable cash flow generation over FY20-23, the statement said

Strong medicine

Patanjali ad ban is the right remedy

Takeda injects hope: Dengue vaccine clinical trials set to begin in India

Biological E will increase manufacturing capacity to up to 50 million doses a year, accelerating Takeda's plans to manufacture 100 million doses annually within the decade

Several pharma cos step up corrective action plans after crackdown by govt

The orders in the state have now been revoked, with the companies undergoing corrective and preventive action (CAPA) processes

Still facing strong headwinds, 2024 sales flat to lower, says Novavax

The company posted a larger-than-expected fourth-quarter loss as revenue lagged analysts' estimates, sending its shares down 26.3% to $4.44 in early trading

Roche Pharma launches new drug for multiple sclerosis treatment in India

With the launch of the new drug, the global pharma company hopes to expand its neurology portfolio and cater to the untapped need of patients facing the disease in India

India to have largest R&D presence outside US by 2025: Bristol Myers CEO

Bristol Myers also operates a research and development centre in Bengaluru in partnership with the Biocon Group's Syngene International